These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21896761)

  • 41. Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.
    Sapparapu G; Planque SA; Nishiyama Y; Foung SK; Paul S
    J Biol Chem; 2009 Sep; 284(36):24622-33. PubMed ID: 19542217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thermodynamics and kinetics of the reaction of a single-chain antibody fragment (scFv) with the leucine zipper domain of transcription factor GCN4.
    Weber-Bornhauser S; Eggenberger J; Jelesarov I; Bernard A; Berger C; Bosshard HR
    Biochemistry; 1998 Sep; 37(37):13011-20. PubMed ID: 9737882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A germline knowledge based computational approach for determining antibody complementarity determining regions.
    Zhao S; Lu J
    Mol Immunol; 2010 Jan; 47(4):694-700. PubMed ID: 19939452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Three-dimensional structure of an Fv from a human IgM immunoglobulin.
    Fan ZC; Shan L; Guddat LW; He XM; Gray WR; Raison RL; Edmundson AB
    J Mol Biol; 1992 Nov; 228(1):188-207. PubMed ID: 1447781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic Engineering of Optimized Autonomous Heavy-Chain Variable Domains.
    Nilvebrant J; Ereño-Orbea J; Gorelik M; Julian MC; Tessier PM; Julien JP; Sidhu SS
    J Mol Biol; 2021 Oct; 433(21):167241. PubMed ID: 34508727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic classification of CDR-L3 in antibodies: implications of the light chain subtypes and the VL-VH interface.
    Kuroda D; Shirai H; Kobori M; Nakamura H
    Proteins; 2009 Apr; 75(1):139-46. PubMed ID: 18798566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context.
    Khalifa MB; Weidenhaupt M; Choulier L; Chatellier J; Rauffer-Bruyère N; Altschuh D; Vernet T
    J Mol Recognit; 2000; 13(3):127-39. PubMed ID: 10867708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
    Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
    J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium.
    Dolezal O; De Gori R; Walter M; Doughty L; Hattarki M; Hudson PJ; Kortt AA
    Protein Eng; 2003 Jan; 16(1):47-56. PubMed ID: 12646692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bovine IgM antibodies with exceptionally long complementarity-determining region 3 of the heavy chain share unique structural properties conferring restricted VH + Vlambda pairings.
    Saini SS; Farrugia W; Ramsland PA; Kaushik AK
    Int Immunol; 2003 Jul; 15(7):845-53. PubMed ID: 12807823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling study of antibody combining sites to (alpha 1-6)dextrans. Predictions of the conformational contribution of VL-CDR3 and J kappa segments to groove-type combining sites.
    Wang D; Hubbard JM; Kabat EA
    J Biol Chem; 1993 Sep; 268(27):20584-9. PubMed ID: 7690758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Russell body inducing threshold depends on the variable domain sequences of individual human IgG clones and the cellular protein homeostasis.
    Stoops J; Byrd S; Hasegawa H
    Biochim Biophys Acta; 2012 Oct; 1823(10):1643-57. PubMed ID: 22728328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies.
    Rouet R; Dudgeon K; Christie M; Langley D; Christ D
    J Biol Chem; 2015 May; 290(19):11905-17. PubMed ID: 25737448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody modeling assessment II. Structures and models.
    Teplyakov A; Luo J; Obmolova G; Malia TJ; Sweet R; Stanfield RL; Kodangattil S; Almagro JC; Gilliland GL
    Proteins; 2014 Aug; 82(8):1563-82. PubMed ID: 24633955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
    Masuda K; Sakamoto K; Kojima M; Aburatani T; Ueda T; Ueda H
    FEBS J; 2006 May; 273(10):2184-94. PubMed ID: 16649995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An autoantibody to single-stranded DNA: comparison of the three-dimensional structures of the unliganded Fab and a deoxynucleotide-Fab complex.
    Herron JN; He XM; Ballard DW; Blier PR; Pace PE; Bothwell AL; Voss EW; Edmundson AB
    Proteins; 1991; 11(3):159-75. PubMed ID: 1749770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure of a non-camelized human M12-V(H) domain at 1.5A resolution.
    Gaur RK
    J Struct Biol; 2005 Oct; 152(1):84-9. PubMed ID: 16183303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.
    Sidhu SS; Li B; Chen Y; Fellouse FA; Eigenbrot C; Fuh G
    J Mol Biol; 2004 Apr; 338(2):299-310. PubMed ID: 15066433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutational effects on inclusion body formation in the periplasmic expression of the immunoglobulin VL domain REI.
    Chan W; Helms LR; Brooks I; Lee G; Ngola S; McNulty D; Maleeff B; Hensley P; Wetzel R
    Fold Des; 1996; 1(2):77-89. PubMed ID: 9079368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
    De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
    J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.